[Prostate cancer-the role of docetaxel on castration-resistant prostate cancer: evaluation of efficacy and subsequent treatment].
Docetaxel is used as a standard therapy for castration-resistant prostate cancer(CRPC). A recent report on the safety and efficacy of decetaxel, based on post-marketing surveillance in Japan, showed similar profiles of PSA response and adverse events. For the determination of efficacy, PSA 30% or 50% response, and an imaging examination are evaluated. One most understand the specific patterns of PSA levels, ie, PSA flare, the transient increase of PSA, and PSA stabilization. Docetaxel would be discontinued based on treatment efficacy, further treatment modalities, adverse events, etc. Now that new hormonal and cytotoxic agents are under development, we must accumulate clinical features of patients treated with docetaxel to construct a better future treatment strategy for CRPC.
Dept. of Urology, Graduate School of Medicine, Gunma University, Gunma, Japan.
Kazuhiro
K
Suzuki
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002369:Castration; D000077143:Docetaxel; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel